SCHEMBL5543931

SCHEMBL5543931

[CH2]c1ccc(Oc2cc(Cl)cc(Cl)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
PGR P06401 1/20 0.38
TSHR P16473 3/20 0.36
TERT O14746 1/20 0.36
ST14 Q9Y5Y6 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
CYP2C9 P11712 2/20 0.35
HSP90AA1 P07900 1/20 0.35
LMNA P02545 1/20 0.35
APEX1 P27695 1/20 0.35
ALDH1A1 P00352 4/20 0.34
MEN1 O00255 2/20 0.34
MAPT P10636 2/20 0.34
KMT2A Q03164 2/20 0.34
AHR P35869 1/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092129 0.83 MAOA (0.58) MAOAMAOBSMN1; SMN2CYP2C9LMNA
SCHEMBL5545085 0.81 AR (0.46) PGRSMN1; SMN2CYP2C9ALDH1A1MEN1
SCHEMBL8155467 0.80 ALDH1A1 (0.47) MAOAMAOBTSHRST14SMN1; SMN2
SCHEMBL10706723 0.80 TSHR (0.57) MAOAMAOBCARM1PRMT6TSHR
SCHEMBL5543172 0.78 CYP2C9 (0.41) MAOAMAOBTSHRSMN1; SMN2CYP2C9
SCHEMBL4044005 0.77 MEN1 (0.64) MAOAMAOBCARM1PRMT6HSP90AA1
SCHEMBL11174697 0.77 AHR (0.57) CARM1PRMT6SMN1; SMN2ALDH1A1MEN1
SCHEMBL12260893 0.77 MAOA (0.41) MAOAMAOBCARM1PRMT6PGR
SCHEMBL12676795 0.77 TEAD4 (0.52) MAOAMAOBCARM1PRMT6TSHR
SCHEMBL10702865 0.77 MAOA (0.71) MAOAMAOBTSHRSMN1; SMN2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOA 2885/4885MAOB 2140/4885CARM1 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.